Drug maker Pfenex announced this week that it has completed its comparative use human factors study for its follow-on teriparatide product, PF708, referencing the osteoporosis drug Forteo.
Drug maker Pfenex announced this week that it has completed its comparative use human factors study for its follow-on teriparatide product, PF708, referencing the osteoporosis drug Forteo. The follow-on was approved by the FDA earlier this month.
According to Pfenex, the study included 102 untrained participants, 52 of whom were patients with osteoporosis and 50 of whom were caregivers. Of the 18 critical tasks assessed, patients using the follow-on had fewer user errors or the same number of errors for 12 (67%) of those tasks. Among caregivers, there were equal numbers of user errors or fewer errors for 15 (83%) of the tasks.
No error difference, in either of the user groups, exceeded the prespecified maximum allowable difference.
In a statement, Pfenex’s chief executive officer, Eef Schimmelpennink, said that the outcome of the study “demonstrates noninferiority between the user interfaces of our product and Forteo,” and that the company will present the data to the FDA as part of a package that the regulator will review to evaluate therapeutic equivalence of the product with its reference.
Because PF708 was approved under the 505(b)(2) approval pathway instead of the biosimilar approval pathway, Pfenex can seek pharmacy-level substitutability for the product without having to undertake the kinds of extra clinical studies that a biosimilar would be subject to if seeking an interchangeable designation; because it is a follow-on and not a biosimilar, PF708 will be evaluated for a determination therapeutic equivalence rather than an interchangeable designation.
When the follow-on was first approved, Schimmelpennink noted that, in order to optimize patient and payer impact, Pfenex’s partner Alvogen will launch PF708 once the FDA has made its decision on therapeutic equivalence for the product.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.